EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder

November 06, 2023

EG 427 today reports positive preclinical results from a dose escalation study of its gene therapy product EG110A for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). The data represents a pivotal milestone and paves the way for an Investigational New Drug (IND) application and initiation of the first clinical study of EG110A in early 2024.

Access full Press Release in English and in French.


Recent posts

EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters

read more >

EG 427 to hold poster presentation on lead asset EG110A at ESGCT
EG 427 to hold poster presentation on lead asset EG110A at ESGCT

read more >

EG 427 announces attendance to multiple upcoming conferences in fall 2023
EG 427 announces attendance to multiple upcoming conferences in fall 2023

read more >

EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting
EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting

read more >

EG 427 announces final Series A closing, achieving €18 million in total funds raised
EG 427 announces final Series A closing, achieving €18 million in total funds raised

read more >

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.